Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 16, 2023; 11(26): 6073-6082
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6073
Continuous renal replacement therapy with oXiris® in patients with hematologically malignant septic shock: A retrospective study
Juan Wang, Shu-Run Wei, Tong Ding, Li-Ping Zhang, Zhi-Hua Weng, Ming Cheng, Yang Zhou, Meng Zhang, Fang-Jun Liu, Bei-Bei Yan, Dan-Feng Wang, Ming-Wen Sun, Wei-Xin Cheng
Juan Wang, Shu-Run Wei, Tong Ding, Li-Ping Zhang, Zhi-Hua Weng, Ming Cheng, Yang Zhou, Meng Zhang, Fang-Jun Liu, Bei-Bei Yan, Dan-Feng Wang, Ming-Wen Sun, Intensive Care Unit, Hebei Yanda Hospital, Langfang 065201, Hebei Province, China
Wei-Xin Cheng, Department of Emergency, Peking University International Hospital, Beijing 102206, China
Author contributions: Wang J and Cheng WX were responsible for research design, statistics and paper writing; Wei SR, Ding T, Zhang LP, Weng ZH, Cheng M, Zhou Y, Zhang M, Liu FJ, Yan BB, Wang DF, and Sun MW were responsible for the collation of data; all authors proofed the manuscript.
Supported by Hebei Health Science and Education Project, No. 20200852.
Institutional review board statement: This study was approved by the hospital’s ethics committee.
Informed consent statement: Patients were not required to provide informed consent for the study because the analysis used anonymous clinical data that were obtained after each patient or their representative family members agreed to the treatment by written consent.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: Some or all data, models, or codes generated or used during the study are available from the corresponding author upon request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Xin Cheng, MD, Doctor, Emergency Department, Peking University International Hospital, No. 1 Life Park Road, Life Science Park of Zhong Guancun, Changping District, Beijing 102206, China. 18911652172@163.com
Received: April 21, 2023
Peer-review started: April 21, 2023
First decision: June 14, 2023
Revised: July 4, 2023
Accepted: July 14, 2023
Article in press: July 14, 2023
Published online: September 16, 2023
Processing time: 139 Days and 23.9 Hours
ARTICLE HIGHLIGHTS
Research background

The mortality rate from septic shock in patients with hematological malignancies (HMs) remains significantly higher than that in patients without HMs.

Research motivation

Continuous renal replacement therapy (CRRT) with oXiris® might shorten the time from resuscitation to fluid negative balance. It may also improve hemodynamic parameters and decrease the blood levels of inflammatory mediators.

Research objectives

This study aimed to explore the effects of CRRT and oXiris® in shortening the resuscitation time as well as a modifier for the host response by reducing levels of inflammation mediators.

Research methods

Patients with HMs who were diagnosed with septic shock and underwent CRRT were divided into two groups based on the hemofilter used. The days with negative balance and total fluid balance after 7 d of CRRT were compared between the groups. The heart rate, norepinephrine dose, Sequential Organ Failure Assessment (SOFA) score, and blood lactic acid levels at different time points in the two groups were also compared.

Research results

The average total fluid balance after 7 d of CRRT in the oXiris® group was significantly lower than that of patients in the M150 hemofilter group, and the SOFA scores of patients after CRRT with oXiris® therapy were significantly lower than those before treatment on day 1 (d1), d3 and d7 after CRRT; these parameters were also significantly lower than those of the control group on d7. Lactate levels after CRRT with oXiris® therapy were significantly lower than those before treatment on d3 and d7 after CRRT. In the oXiris® group, procalcitonin levels decreased on d7, and interleukin-6 and tumor necrosis factor- levels reduced significantly on both d3 and d7 after oXiris® treatment.

Research conclusions

CRRT with oXiris® hemofilter might improve the hemodynamic parameters and play a role in shortening the resuscitation period, thus decreasing the total fluid balance in the resuscitation phase.

Research perspectives

CRRT with an oXiris® hemofilter may be used as a host response modulation method in patients with septic shock and HM. This may improve hemodynamic parameters by reducing the levels of inflammatory mediators.